Y. Al Malik, Ibtisam A. Al Thubaiti, M. Alammari, Norah Al Fugham, Eman N. Ali, D. Alissa, Salman Aljarallah, A. Al-jedai, Maeed A. AlKathiri, M. AlKhawajah, Mousa A. Almejally, H. Al-Mudaiheem, Hessa S. Al Otaibi, G. Altowaijri, Rumaiza H. Al Yafeai, Mohammed A. Babakkor, S. Bohlega, R. Bunyan, E. Cupler, Mohammed A. Hakami, Abid M. Kareem, Amr M. Khardaly, S. Makkawi, Leena H. Saeed, J. Saeedi, E. Shosha, Mohammad A. Al Jumah
{"title":"Saudi Consensus Recommendations on the Management of Multiple Sclerosis: Disease-Modifying Therapies and Management of Relapses","authors":"Y. Al Malik, Ibtisam A. Al Thubaiti, M. Alammari, Norah Al Fugham, Eman N. Ali, D. Alissa, Salman Aljarallah, A. Al-jedai, Maeed A. AlKathiri, M. AlKhawajah, Mousa A. Almejally, H. Al-Mudaiheem, Hessa S. Al Otaibi, G. Altowaijri, Rumaiza H. Al Yafeai, Mohammed A. Babakkor, S. Bohlega, R. Bunyan, E. Cupler, Mohammed A. Hakami, Abid M. Kareem, Amr M. Khardaly, S. Makkawi, Leena H. Saeed, J. Saeedi, E. Shosha, Mohammad A. Al Jumah","doi":"10.3390/ctn6040027","DOIUrl":null,"url":null,"abstract":"For the past 10 years, disease-modifying therapy (DMT) options for multiple sclerosis (MS) have grown remarkably where DMTs have been shown to reduce the risk of MS relapses. MS patients are advised to begin treatment with a DMT shortly after diagnosis to limit the possibility of disease progression over time. While patients with radiologically isolated syndrome do not require pharmacologic treatment, high-risk patients with clinically isolated syndrome are advised to start DMTs. This article provides evidence-based recommendations for DMT use in MS management, helping healthcare practitioners advise patients on treatment decisions. We aim to provide recommendations for the management of acute MS relapses. The recommendations herein were developed following the gathering of a panel of experts after evaluating international guidelines, and the latest evidence was collected through a comprehensive literature review.","PeriodicalId":242430,"journal":{"name":"Clinical and Translational Neuroscience","volume":"21 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2022-12-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical and Translational Neuroscience","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3390/ctn6040027","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1
Abstract
For the past 10 years, disease-modifying therapy (DMT) options for multiple sclerosis (MS) have grown remarkably where DMTs have been shown to reduce the risk of MS relapses. MS patients are advised to begin treatment with a DMT shortly after diagnosis to limit the possibility of disease progression over time. While patients with radiologically isolated syndrome do not require pharmacologic treatment, high-risk patients with clinically isolated syndrome are advised to start DMTs. This article provides evidence-based recommendations for DMT use in MS management, helping healthcare practitioners advise patients on treatment decisions. We aim to provide recommendations for the management of acute MS relapses. The recommendations herein were developed following the gathering of a panel of experts after evaluating international guidelines, and the latest evidence was collected through a comprehensive literature review.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
